Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 2/20 | 0.38 |
| ▸ | FLT1 | P17948 | 2/20 | 0.38 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.38 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.34 |
| ▸ | TOP2A | P11388 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL907034 | 0.76 | ERBB2 (0.38) | ERBB2FLT1EPHA2KDREPHB4 | |
| SCHEMBL4939815 | 0.75 | ERBB2 (0.37) | ERBB2FLT1EPHA2KDREPHB4 | |
| SCHEMBL3262065 | 0.75 | ERBB2 (0.37) | ERBB2FLT1EPHA2KDREPHB4 | |
| SCHEMBL372114 | 0.75 | ERBB2 (0.37) | ERBB2FLT1EPHA2KDREPHB4 | |
| SCHEMBL371746 | 0.74 | ALDH1A1 (0.36) | ERBB2FLT1EPHA2KDREPHB4 | |
| SCHEMBL13435540 | 0.72 | TOP2A (0.33) | TOP2A | |
| SCHEMBL15754838 | 0.70 | FKBP1A (0.30) | FKBP1A | |
| SCHEMBL22029081 | 0.70 | PDK2 (0.37) | FKBP1ATOP2AMEN1KMT2A | |
| SCHEMBL5676774 | 0.70 | PDK2 (0.37) | FKBP1ATOP2AMEN1KMT2A | |
| SCHEMBL5676651 | 0.70 | PDK2 (0.37) | FKBP1ATOP2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124482-B2 | C-met modulators and methods of use | EXELIXIS, INC. (US) | 2021-09-21 | — | — | US | disclosed |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. | 2021-08-19 | — | — | US | disclosed |
| US-20200331860-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2020-10-22 | — | — | US | disclosed |
| EP-1521747-B1 | RECEPTOR-TYPE KINASE MODULATORS AND METHODS OF USE | SYMPHONY EVOLUTION INC (US) | 2018-09-05 | — | — | EP | disclosed |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | EXELIXIS INC (US) | 2017-12-14 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2409704-B1 | c-Met modulators and methods of use | EXELIXIS INC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-9359332-B2 | Processes for the preparation of substituted quinazolines | SYMPHONY EVOLUTION, INC. (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2016-05-12 | — | — | US | disclosed |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. | 2015-12-31 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC (US) | 2009-04-23 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| EP-1874759-A1 | C-MET MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
| WO-2006108059-A1 | C-MET MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200331860-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ERBB2 56/4885FLT1 2/4885EPHA2 610/4885 |
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | ERBB2 56/4885FLT1 2/4885EPHA2 610/4885 |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | ERBB2 5/4885FLT1 22/4885EPHA2 2/4885 |
| US-20150376133-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ERBB2 56/4885FLT1 2/4885EPHA2 610/4885 |
| US-20170355678-A1 | C-Met Modulators and Methods of Use | FLT4, FLT1, MET | ERBB2 56/4885FLT1 2/4885EPHA2 610/4885 |
| US-20210253530-A9 | C-MET MODULATORS AND METHODS OF USE | FLT4, FLT1, MET | ERBB2 56/4885FLT1 2/4885EPHA2 610/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | ERBB2 62/4885FLT1 46/4885EPHA2 254/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | ERBB2 96/4885FLT1 3/4885EPHA2 746/4885 |
| US-20160129032-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | ERBB2 5/4885FLT1 22/4885EPHA2 2/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ERBB2 109/4885FLT1 3/4885EPHA2 834/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | ERBB2 109/4885FLT1 3/4885EPHA2 834/4885 |
| US-11124482-B2 | C-met modulators and methods of use | FLT4, FLT1, MET | ERBB2 56/4885FLT1 2/4885EPHA2 610/4885 |
| US-20090105299-A1 | c-MET MODULATORS AND METHODS OF USE | FLT4, MET, FLT1 | ERBB2 96/4885FLT1 3/4885EPHA2 746/4885 |
| US-20070179130-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, KDR | ERBB2 21/4885FLT1 4/4885EPHA2 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.